Background: Only one-third of patients with major depressive disorder (MDD) achieve remission with initial treatment. Consequently, current clinical practice relies on a "trial-and-error" approach to identify an effective treatment for each patient. The purpose of this report was to determine whether we could identify a set of clinical and biological parameters with potential clinical utility for prescription of exercise for treatment of MDD in a secondary analysis of the Treatment with Exercise Augmentation in Depression (TREAD) trial.
INTRODUCTION
Major depressive disorder (MDD) results in significant disease burden including impaired psychosocial functioning (Judd et al., 2008; Wells et al., 1989) , greater risk of future MDD episodes (Burcusa & Iacono, 2007) , and poorer general health outcomes (Barth, Schumacher, & Herrmann-Lingen, 2004; Cuijpers & Smit, 2002; Koponen, Jokelainen, Keinanen-Kiukaanniemi, & Vanhala, 2010; Pinquart & Duberstein, 2010) . These detrimental effects of MDD result in an annual economic burden of $83 billion in the United States (Greenberg et al., 2003) .
One factor that greatly contributes to significant disease burden of MDD is the heterogeneous treatment response patients experience with current treatment options. Initial response rates to treatment with SSRIs are approximately 50%, with remission rates for SSRI treatment ranging from 30 to 35% (Thase et al., 2005) . Similarly, exercise is an efficacious alternative treatment for MDD, with remission rates to exercise treatment in randomized controlled trials similar to those observed with SSRIs (Rethorst, Wipfli, & Landers, 2009 ). Augmentation or treatment switches are therefore often necessary for a significant portion of patients with MDD.
This "trial-and-error" process results in prolonged disease presence that could be averted if patients received a personalized prescription for the treatment most likely to be effective and/or avoid treatments that are likely to fail. Many individual patient characteristics are associated with desired treatment outcomes of SSRIs (Papakostas & Fava, 2008 ) and exercise (Schuch, (Saveanu et al., 2015; Wallace, Frank, & Kraemer, 2013) .
The purpose of this report was to determine whether we could identify a set of predefined clinical and biological parameters that might have clinical utility for prescription of exercise for treatment of depression. This secondary analysis utilized data from the Treatment with Exercise Augmentation for Depression (TREAD) trial (Trivedi, Greer, et al., 2006; Trivedi et al., 2011) . We assessed the utility of predictors to identify two distinct patient subgroups: (1) patients for whom exercise would likely be beneficial and (2) patients who would be unlikely to benefit from exercise. We reduced the heterogeneity of the sample by eliminating those patients for whom the efficacy of exercise was uncertain (i.e., those with only marginal improvement in depressive symptomatology).
MATERIALS AND METHODS
A comprehensive description of the TREAD trial methodology has been published (Trivedi, Greer, et al., 2006; Trivedi et al., 2011) . Details relevant to the current analysis are provided below.
Participants
Individuals meeting the following inclusion/exclusion criteria were eligible for participation. Inclusion criteria were (1) age 18-70 years, (2) diagnosis of nonpsychotic MDD, (3) 2-6 months of treatment with an SSRI with at least 6 weeks of adequate dose, (4) residual depressive symptomatology (defined as a score of ≥14 on the Hamilton Depression Rating Scale), (5) not engaged in regular exercise, (6) capable of exercise, and (7) able and willing to provide informed consent. Exclusion criteria included (1) significant medical condition contraindicative of exercise, (2) depression due to a comorbid psychiatric disorder, (3) current pharmacological treatment other than SSRI, (4) failure of two or more pharmacological treatments of adequate dose and duration during current depressive episode, and (5) pregnant or planned pregnancy.
Potential baseline predictors
An initial pool of 30 baseline characteristic variables was selected for analysis as potential predictors of remission and nonresponse (Table 1) .
Full description of these measures have been published previously Rethorst, Sunderajan, et al., 2013; Rethorst, Toups, et al., 2013; Suterwala et al., 2016; Toups et al., 2011; Trivedi, Greer, et al., 2006; Trivedi et al., 2011) . These variables were selected based on the results of these previously published findings and other factors that have been associated with treatment outcomes in depression (Sotsky et al., 1991; Trivedi, Rush, et al., 2006; Warden et al., 2007) .
Intervention
Participants were randomized to one of two exercise dose groups for 12 weeks: 4 or 16 kcal/kg/week. Participants completed the entire dose in supervised sessions during week 1, completed two supervised sessions during week 2, and completed one supervised session during weeks 3-12. The remaining exercise dose was completed in unsupervised exercise sessions. Exercise intensity was self-selected and monitored with a heart rate monitor (Polar 610i) in supervised and unsupervised sessions.
Statistical analysis
To minimize heterogeneity in the sample, we focused on two groups within the sample; those defined as treatment successes (those who achieved remission defined as a score of ≤12 on the IDS-C) or treatment failures (those who experienced less than a 30% drop in IDS-C total score by the end of their last week in the program ("nonresponders"). Of the 122 patients, 36 were remitters (29.5%), 56 were nonresponders (45.9%), and 30 were neither (24.6%).
To utilize the maximum potential of the data, we followed the recommendations of Schomaker and Heumann (2014) and carried out both multiple imputation and the bootstrap. Starting with the initial pool of 30 variables, a filtering process was used to identify a subset of variables (after standardizing them to have a mean of 0 and standard deviation of 1) that seemed to contain predictive power. The process was carried out on each bootstrapped, multiply imputed sample and utilized both the least absolute shrinkage and selection operator, or LASSO (Tibshirani, 1996) and random forests (Breiman, 2001 ); these two methods were chosen so that both parametric and nonparametric modelling techniques were represented. We deemed predictive power to be added by variables with large effect sizes in both modeling paradigms. The LASSO was implemented via the glmnet package in R (Friedman, Hastie, & Tibshirani, 2009; Friedman, Hastie, & Tibshirani, 2010) with the penalty parameter chosen via 10-fold crossvalidation. Random forests were implemented using the randomForest function (Liaw & Wiener, 2002) . The ranks of the relative strengths of the variables in each method were summed and the variables for inclusion in the final models were selected by identifying a natural "elbow" in the rank sums. Note that this process was repeated twice -once using remission status as the dependent variable and once using nonresponse status as the dependent variable.
After selecting a set of variables for each classification problem, multiple imputation in combination with separate logistic regression models was used to estimate the probabilities of both remitting and nonresponding for the subjects in the study.
Because the patients for whom clinicians can take action to prescribe a treatment are those who can be predicted with substantial certainty to either remit or to have no meaningful benefit (i.e., no substantial response) to a particular treatment, we utilized the ratio of the estimated probability of remission to the estimated probability of no substantial response, subject to a minimum probability threshold: Predicted Group
Remitter,
where a is the largest ratio value for which we would not call someone a substantial nonresponder, b the smallest ratio value for which we would call someone a remitter, and c the minimum probability threshold we require to call someone a remitter or nonresponder, given that the appropriate ratio threshold is met. Assume that a ≤ b. With respect to random forests, we followed the same protocol, but instead tracked the mean decrease in Gini index 1 for each variable in each imputation of each bootstrap sample and present the results in Tables 4 and 5 .
There was a strong amount of agreement between the two variable filtering approaches. The following variables increased the probability of remission: higher baseline BDNF levels, higher baseline IL-1B levels, lower baseline IDS-SR total score, and higher positive affect following initial exercise (PANAS). A similar process yielded the following variables that predicted high probability of nonresponse: higher cardiorespiratory fitness (VO 2 max), lower baseline IL-6, lower baseline BDNF levels, and lower positive affect following exercise (PANAS). An ROC analysis (Figure 1 ) was carried out on the average fitted probabilities, with an AUC of 0.785 for the remission model and 0.710 for the nonresponse model; this indicates a moderate fit to the data. Figure 2 shows the distribution of the ratios for the three groups of people. The distributions show a narrow range of ratios for the nonresponders, F I G U R E 1 Estimated density plots for remission and nonresponse ratios F I G U R E 2 ROC curves for remission and nonresponse suggesting they may be easier to identify using this metric. The remitters have the widest range of ratios but are skewed more toward the larger ratios, and the "neither" group was somewhere in between.
Actionable decisions can be made when PPV or NPV are large for a substantial portion of true remitters or substantial nonresponders.
Specifically, we considered this to be at least 70% PPV and NPV at sensitivities and specificities of at least 20%. Table 6 summarizes the optimal combination of cut points as specified in equation (1). Using these cut points results in 70.6% of predicted remitters actually achieving remission and 77.8% of predicted nonresponders failing to respond to treatment.
TA B L E 6 -Efficacy of final models to predict remission and nonresponse 
DISCUSSION
The aim of this study was to determine whether we could identify clinical and biological characteristics that could collectively be used to predict treatment response to exercise for patients with nonremitted MDD. Using only six variables identified using data-driven procedures,
we were able to use the proposed methodology to obtain greater than 70% positive predictive and negative predictive values for more than 25% of the population in the study. These results suggest that there is substantial potential clinical utility, as one quarter of patients who would not respond to exercise could instead be offered an alternative treatment should these results be replicable.
The goal of this approach would be to ultimately create a clinical decision tool that would assist clinicians in choosing treatment for patients based on the presence of these characteristics. While individual predictors of treatment response to exercise (Schuch et al., 2016) have been identified, these individual characteristics do not have the predictive power to be of clinical utility. Our results suggest that by combining multiple patient characteristics into a decision model can provide the necessary level of certainty for the likely outcome.
Our findings also provide some insight into the potential mechanisms underlying the antidepressant effects of exercise. Inflammatory markers and BDNF have both been suggested as potential mechanisms, as reviewed by Medina, Jacquart, and Smits (2015) . Our previous analyses of the TREAD data found each were associated with treatment response (Rethorst, Toups, et al., 2013; Toups et al., 2011) .
In addition, a recent paper form the Regassa study (Hallgren et al., 2015) also found elevated baseline inflammation (IL-6) to predict better treatment response to exercise (Lavebratt et al., 2017) . The fact that these markers remained among the most significant predictors of treatment outcomes when also considering several other baseline characteristics as potential predictors reinforces the role of these biological factors in the antidepressant effects of exercise.
While previous research has similarly aimed to identify models to predict treatment outcomes to antidepressant medication and psychotherapy in MDD (Wallace et al., 2013) , we are not aware of reports focusing on remission versus "total" lack of response. Given that other treatment options are be available in clinical settings (i.e., antidepressant medications, psychotherapy, etc.), this approach would optimally be implemented in conjunction with tools that predict treatment response to these other treatments. The utility of a tool to aid in clinical decision-making for MDD is enhanced if the probability of treatment outcomes were available for multiple treatment options. by the lasso to have some predictive power.
CONCLUSION
Our results suggest it is possible to identify a subset of patients with MDD for which exercise is unlikely to be an effective treatment.
Avoiding ineffective treatment options helps to properly target the treatment to patients who are more responsive, which should enhance outcomes and perhaps reduce costs compared to the current "trial-and-error" approach to treatment selection.
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